A Pillar Of Eisai’s Growth Strategy Misses Primary Endpoint In First Phase III Trial
Eisai-acquired Morphotek lead candidate farletuzumab sees disappointing results in platinum-sensitive ovarian cancer.
Eisai-acquired Morphotek lead candidate farletuzumab sees disappointing results in platinum-sensitive ovarian cancer.